Zacks Rating on MiMedx Group Inc (MDXG)

MiMedx Group Inc (MDXG) has an average broker rating of 1.4, which is interpreted as a Strong Buy, as rated by 5 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

MiMedx Group Inc (MDXG) : Average target price received by MiMedx Group Inc (MDXG) is $11.6 with an expected standard deviation of $1.52. The most aggressive target on the stock is $13, whereas the most downbeat target is $9. 5 financial analysts are currently covering the stock.


Shares of MiMedx Group, Inc. appreciated by 1.21% during the last five trading days but lost 1.57% on a 4-week basis. MiMedx Group, Inc. has dropped 1.19% during the last 3-month period . Year-to-Date the stock performance stands at -19.96%. MiMedx Group Inc (NASDAQ:MDXG): On Tuesdays trading session , Opening price of the stock was $7.57 with an intraday high of $7.57. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $7.38. However, the stock managed to close at $7.5, a loss of 0.27% for the day. On the previous day, the stock had closed at $7.52. The total traded volume of the day was 356,027 shares.

MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.